The FDA on January 12, 2024, approved KEYTRUDA® (Pembrolizumab) with chemoradiotherapy for patients with FIGO 2014 Stage III-IVA Cervical cancer. KEYTRUDA® is a product of Merck.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement
Advertisement
The FDA on January 12, 2024, approved KEYTRUDA® (Pembrolizumab) with chemoradiotherapy for patients with FIGO 2014 Stage III-IVA Cervical cancer. KEYTRUDA® is a product of Merck.
Advertisement